Doravirine, sold under the brand name Pifeltro, is a
non-nucleoside reverse transcriptase inhibitor medication developed by
Merck & Co. for use in the treatment of
HIV/AIDS
Human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV), a retrovirus. Following initial infection an individual ...
.
Doravirine was approved for medical use in the United States in August 2018.
References
External links
*
Nitriles
Trifluoromethyl compounds
Merck & Co. brands
Nitrogen heterocycles
Non-nucleoside reverse transcriptase inhibitors
Chloroarenes
Phenol ethers
{{antiinfective-drug-stub